Astellas Mulls Potential Impact Of New US CRL For Izervay
Refiling Considered But Timing Unclear
Astellas's C5 inhibitor faces another approval challenge, this time for a supplemental filing in the US, following the withdrawal of a European submission, although it continues to do well in what is its only market so far.
